{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:16Z","timestamp":1781650636177,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose of review: Treatment of meningioma is rapidly evolving, as molecular classification, functional imaging, and radiotherapeutic techniques have undergone recent advances. The purpose of this review is to integrate these developments with clinical trial data to guide modern radiotherapy approaches. We specifically sought to address how new biological and imaging insights inform radiation planning, dose, and outcomes.<\/jats:p>\n                  <jats:p>Recent findings: Molecular classification provides prognostic insights beyond the classic WHO grading system. DOTATATE-PET has proven valuable for accurate delineation of tumor extent and biologically active regions, directly impacting radiotherapy planning. Recent clinical studies highlight the potential for improved local control with dose escalation and PET-guided planning. Ongoing clinical trials in the intact and salvage settings will provide further insight into the integration of imaging, biology, and radiotherapy.<\/jats:p>\n                  <jats:p>Summary: Radiotherapy for meningiomas is transitioning into a precision discipline, leveraging molecular and imaging biomarkers for individualized care. Integration of DOTATATE-PET, advanced radiation delivery techniques, and biologically guided dose escalation are redefining standards. Future research will test whether personalized, biomarker-driven radiotherapy can significantly improve outcomes in aggressive and recurrent meningiomas.<\/jats:p>","DOI":"10.1007\/s11912-026-01766-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:17:10Z","timestamp":1776741430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances"],"prefix":"10.1007","volume":"28","author":[{"given":"Bradley","family":"Eckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"10","key":"1766_CR1","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/neuonc\/noae082","volume":"26","author":"W JZ","year":"2024","unstructured":"JZ W, DR APL, KM RFS, Meningioma WRG. International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neurooncology. 2024;26(10):1742\u201380. https:\/\/doi.org\/10.1093\/neuonc\/noae082.","journal-title":"Neurooncology"},{"issue":"8","key":"1766_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"L DN","year":"2021","unstructured":"DN L. The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology. 2021;23(8):1231\u201351. https:\/\/doi.org\/10.1093\/neuonc\/noab106.","journal-title":"Neurooncology"},{"issue":"11","key":"1766_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","volume":"18","author":"LB Nabors","year":"2020","unstructured":"Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(11):1537\u201370. https:\/\/doi.org\/10.6004\/jnccn.2020.0052.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"1766_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S1470-2045(25)00267-0","volume":"26","author":"C Gui","year":"2025","unstructured":"Gui C, Wang JZ, Patil V, Landry AP, Singh O, Castelo-Branco P, et al. Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study. Lancet Oncol. 2025;26(9):1191\u2013203. https:\/\/doi.org\/10.1016\/S1470-2045(25)00267-0.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S1470-2045(25)00422-X","volume":"26","author":"KJ Groff","year":"2025","unstructured":"Groff KJ, Patel RV, Feng Y, Ghosh HS, Millares Chavez MA, O\u2019Brien J, et al. The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis. Lancet Oncol. 2025;26(9):1178\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(25)00422-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1766_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F S","year":"2017","unstructured":"F S, K S, I M. DNA methylation-based classification and grading system for meningioma. Lancet Oncol. 2017;18(5):682\u201394. https:\/\/pubmed.ncbi.nlm.nih.gov\/28314689\/","journal-title":"Lancet Oncol"},{"issue":"7874","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"YM F N","year":"2021","unstructured":"F N YM. Meningioma classification by DNA methylation profiling shows clinically relevant groups. Nature. 2021;597(7874):119\u201325. https:\/\/doi.org\/10.1038\/s41586-021-03850-3.","journal-title":"Nature"},{"key":"1766_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03167-4","author":"W JZ","year":"2024","unstructured":"JZ W, C G. Molecular classification to refine surgical and radiotherapy care for meningioma. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03167-4.","journal-title":"Nat Med"},{"key":"1766_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac089","author":"Y MW","year":"2022","unstructured":"MW Y. A 34-gene expression signature predicts benefit from radiotherapy in meningioma. Neurooncology. 2022. https:\/\/doi.org\/10.1093\/neuonc\/noac089.","journal-title":"Neurooncology"},{"issue":"6","key":"1766_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/jamaoncol.2025.0329","volume":"11","author":"AP Landry","year":"2025","unstructured":"Landry AP, Wang JZ, Patil V, Liu J, Gui C, Ellenbogen Y, et al. Chromosome 1p Loss and 1q Gain for Grading of Meningioma. JAMA Oncol. 2025;11(6):644\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0329.","journal-title":"JAMA Oncol"},{"issue":"11","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"RGPS MD","year":"2021","unstructured":"MD RGPS EANO guideline on the diagnosis and management of meningiomas. Neurooncology. 2021;23(11):1821\u201334. . https:\/\/doi.org\/10.1093\/neuonc\/noab150.","journal-title":"Neurooncology"},{"key":"1766_CR12","unstructured":"2017. https:\/\/clinicaltrials.gov\/study\/NCT03180268"},{"key":"1766_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jon.13570","author":"B TA","year":"2024","unstructured":"TA B. Intracranial meningioma: A review of recent and emerging data on the utility of PET imaging. J Neuroimaging. 2024. https:\/\/doi.org\/10.1111\/jon.13570.","journal-title":"J Neuroimaging"},{"issue":"3","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"R W","year":"2015","unstructured":"W R, VM S. 68Ga-DOTATATE uptake in meningioma correlates with SSTR2 expression and enables accurate delineation. J Nucl Med. 2015;56(3):347\u201353. https:\/\/doi.org\/10.2967\/jnumed.114.149120.","journal-title":"J Nucl Med"},{"issue":"10","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.2967\/jnumed.116.189365","volume":"58","author":"K WG","year":"2017","unstructured":"WG K, NL J. Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI. J Nucl Med. 2017;58(10):1580\u20135. https:\/\/doi.org\/10.2967\/jnumed.116.189365.","journal-title":"J Nucl Med"},{"issue":"1","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijrobp.2012.03.043","volume":"85","author":"R G, N W, U M-L","year":"2013","unstructured":"R G, N W, U M-L. Target volume delineation of skull base meningiomas with 68Ga-DOTATOC PET\/CT: Impact on radiotherapy planning. Int J Radiat Oncol Biol Phys. 2013;85(1):68\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.03.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ijrobp.2006.01.036","volume":"65","author":"MH S M-Z, A Z-dB","year":"2006","unstructured":"S M-Z, A Z-dB MH. Target definition of meningiomas by PET with 68Ga-DOTATOC for stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):911\u20134. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.01.036.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1016\/j.ijrobp.2022.04.033","volume":"112","author":"P HK","year":"2022","unstructured":"HK P, TJC W. 68Ga-DOTATATE PET-based radiation contouring creates more precise radiation volumes for meningioma patients. Int J Radiat Oncol Biol Phys. 2022;112(2):E63\u20134. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.033.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13014-021-01875-6","volume":"16","author":"K ES","year":"2021","unstructured":"ES K, SE C. DOTATATE PET\/CT for radiation planning and response assessment in meningioma. Radiat Oncol. 2021;16(1):191. https:\/\/doi.org\/10.1186\/s13014-021-01875-6.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1766_CR20","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.1038\/s41598-022-13467-9","volume":"12","author":"K SH","year":"2022","unstructured":"SH K, HS L, SW O. Evaluating diagnostic accuracy of quantitative 68Ga-DOTATATE PET\/MRI analysis in meningioma. Sci Rep. 2022;12(1):9165. https:\/\/doi.org\/10.1038\/s41598-022-13467-9.","journal-title":"Sci Rep"},{"issue":"1","key":"1766_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00259-019-04539-0","volume":"47","author":"K KA","year":"2020","unstructured":"KA K. 68Ga-DOTATATE PET enables precise target volume delineation and improves outcomes in low-grade meningioma. Eur J Nucl Med Mol Imaging. 2020;47(1):86\u201394. https:\/\/doi.org\/10.1007\/s00259-019-04539-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"vdab024","DOI":"10.1093\/noajnl\/vdab024","volume":"3","author":"M H","year":"2021","unstructured":"H M, A M, N T. Integration of DOTATATE PET with fractionated stereotactic radiotherapy for meningioma: disease control and functional outcomes. Neuro-Oncology Adv. 2021;3(1):vdab024. https:\/\/doi.org\/10.1093\/noajnl\/vdab024.","journal-title":"Neuro-Oncology Adv"},{"issue":"8","key":"1766_CR23","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/neuonc\/noae067","volume":"26","author":"JI SJ","year":"2024","unstructured":"SJ JI. DOTATATE PET\/MRI\u2013guided radiosurgical planning and response assessment in meningiomas. Neurooncology. 2024;26(8):1526\u201335. https:\/\/doi.org\/10.1093\/neuonc\/noae067.","journal-title":"Neurooncology"},{"issue":"12","key":"1766_CR24","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1007\/s00259-024-06783-x","volume":"51","author":"NL Albert","year":"2024","unstructured":"Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024;51(12):3662\u201379. https:\/\/doi.org\/10.1007\/s00259-024-06783-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2024.11.023","volume":"122","author":"P HK","year":"2025","unstructured":"HK P, DR R, TJC W. Consensus radiation treatment planning guidelines utilizing 68Ga-DOTATATE PET\/CT for resected meningiomas. Int J Radiat Oncol Biol Phys. 2025;122(1):150\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/neuonc\/noac137","volume":"25","author":"CL Rogers","year":"2023","unstructured":"Rogers CL, Pugh SL, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Low-risk meningioma: Initial outcomes from NRG Oncology\/RTOG 0539. Neuro Oncol. 2023;25(1):137\u201345. https:\/\/doi.org\/10.1093\/neuonc\/noac137.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1766_CR27","doi-asserted-by":"publisher","first-page":"vdad125","DOI":"10.1093\/noajnl\/vdad125","volume":"5","author":"C WC","year":"2023","unstructured":"WC C, ME D. Radiotherapy and radiosurgery for meningiomas. Neuro-Oncology Adv. 2023;5(1):vdad125. https:\/\/doi.org\/10.1093\/noajnl\/vdad125.","journal-title":"Neuro-Oncology Adv"},{"issue":"1","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijrobp.2018.01.053","volume":"110","author":"M MT","year":"2021","unstructured":"MT M. Single- and multi-fraction stereotactic radiosurgery dose tolerances of the optic pathways. Int J Radiat Oncol Biol Phys. 2021;110(1):87\u201399. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1766_CR29","doi-asserted-by":"publisher","first-page":"e929","DOI":"10.1016\/j.wneu.2022.05.064","volume":"164","author":"YJ Vaishnav","year":"2022","unstructured":"Vaishnav YJ, Singh R, Didwania P, Lehrer EJ, Bakaeva T, Harris TJ, et al. Radiotherapy and Radiosurgery in the Management of Optic Nerve Sheath Meningiomas: An International Systematic Review and Meta-Analysis of Twenty Studies. World Neurosurg. 2022;164:e929\u201344. https:\/\/doi.org\/10.1016\/j.wneu.2022.05.064.","journal-title":"World Neurosurg"},{"key":"1766_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jocn.2020.09.058","volume":"81","author":"HY Chen","year":"2020","unstructured":"Chen HY, Chuang CC, Chen HC, Wei KC, Chang CN, Liu ZH, et al. Clinical outcomes of fractionated stereotactic radiosurgery in treating perioptic meningiomas and schwannomas: A single-institutional experience. J Clin Neurosci. 2020;81:409\u201315. https:\/\/doi.org\/10.1016\/j.jocn.2020.09.058.","journal-title":"J Clin Neurosci"},{"issue":"4","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/neuros\/nyaa544","volume":"88","author":"A Bunevicius","year":"2021","unstructured":"Bunevicius A, Anand RK, Suleiman M, Nabeel AM, Reda WA, Tawadros SR, et al. Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study. Neurosurgery. 2021;88(4):828\u201337. https:\/\/doi.org\/10.1093\/neuros\/nyaa544.","journal-title":"Neurosurgery"},{"issue":"1","key":"1766_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijrobp.2018.01.053","volume":"110","author":"MT Milano","year":"2021","unstructured":"Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tome WA, et al. Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways. Int J Radiat Oncol Biol Phys. 2021;110(1):87\u201399. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.053.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1766_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/neuros\/nyaa169","volume":"87","author":"M Marchetti","year":"2020","unstructured":"Marchetti M, Sahgal A, De Salles AAF, Levivier M, Ma L, Paddick I, et al. Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline. Neurosurgery. 2020;87(5):879\u201390. https:\/\/doi.org\/10.1093\/neuros\/nyaa169.","journal-title":"Neurosurgery"},{"issue":"5","key":"1766_CR34","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.wneu.2014.12.037","volume":"83","author":"S Hasan","year":"2015","unstructured":"Hasan S, Young M, Albert T, Shah AH, Okoye C, Bregy A, et al. The role of adjuvant radiotherapy after gross total resection of atypical meningiomas. World Neurosurg. 2015;83(5):808\u201315. https:\/\/doi.org\/10.1016\/j.wneu.2014.12.037.","journal-title":"World Neurosurg"},{"issue":"3","key":"1766_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.054","volume":"103","author":"R CL","year":"2018","unstructured":"CL R, WA PZ. Intermediate-risk meningioma: Initial outcomes from NRG Oncology\/RTOG 0539. Int J Radiat Oncol Biol Phys. 2018;103(3):861\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.11.054.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1766_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.radonc.2019.12.002","volume":"145","author":"RM C","year":"2020","unstructured":"C RM. EORTC 22042\u201326042: Adjuvant radiotherapy for atypical meningioma after gross total resection \u2013 phase II results. Radiother Oncol. 2020;145:155\u201361. https:\/\/doi.org\/10.1016\/j.radonc.2019.12.002.","journal-title":"Radiother Oncol"},{"key":"1766_CR37","doi-asserted-by":"publisher","first-page":"877244","DOI":"10.3389\/fonc.2022.877244","volume":"12","author":"B HK","year":"2022","unstructured":"HK B, JH C. Adjuvant radiotherapy versus surveillance for grade 2 meningiomas: a multicenter propensity score\u2013matched study. Front Oncol. 2022;12:877244. https:\/\/doi.org\/10.3389\/fonc.2022.877244.","journal-title":"Front Oncol"},{"issue":"1","key":"1766_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11060-021-03724-5","volume":"154","author":"JL JW","year":"2021","unstructured":"JW JL, CK K. Adjuvant radiotherapy after gross total resection for atypical meningioma: a single-institution experience. J Neurooncol. 2021;154(1):55\u201363. https:\/\/doi.org\/10.1007\/s11060-021-03724-5.","journal-title":"J Neurooncol"},{"key":"1766_CR39","doi-asserted-by":"publisher","first-page":"702732","DOI":"10.3389\/fonc.2021.702732","volume":"11","author":"Q H","year":"2021","unstructured":"H Q, Z Y, L J. Meta-analysis of adjuvant radiotherapy after gross total resection of atypical meningioma. Front Oncol. 2021;11:702732. https:\/\/doi.org\/10.3389\/fonc.2021.702732.","journal-title":"Front Oncol"},{"issue":"5","key":"1766_CR40","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00701-021-05170-6","volume":"164","author":"S Y","year":"2022","unstructured":"Y S, M Z, J C. Adjuvant radiotherapy improves outcomes in atypical meningioma: a systematic review and meta-analysis. Acta Neurochir. 2022;164(5):1261\u201371. https:\/\/doi.org\/10.1007\/s00701-021-05170-6","journal-title":"Acta Neurochir"},{"issue":"1","key":"1766_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13014-021-01759-9","volume":"16","author":"C SW","year":"2021","unstructured":"SW C, KM K, MS K. Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. Radiat Oncol. 2021;16(1):34. https:\/\/doi.org\/10.1186\/s13014-021-01759-9.","journal-title":"Radiat Oncol"},{"key":"1766_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s13063-015-1040-3","volume":"16","author":"MD Jenkinson","year":"2015","unstructured":"Jenkinson MD, Javadpour M, Haylock BJ, Young B, Gillard H, Vinten J, et al. The ROAM\/EORTC-1308 trial: Radiation versus Observation following surgical resection of Atypical Meningioma: study protocol for a randomised controlled trial. Trials. 2015;16:519. https:\/\/doi.org\/10.1186\/s13063-015-1040-3.","journal-title":"Trials"},{"issue":"3","key":"1766_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijrobp.2021.01.048","volume":"110","author":"RO Kowalchuk","year":"2021","unstructured":"Kowalchuk RO, Shepard MJ, Sheehan K, Sheehan D, Faramand A, Niranjan A, et al. Treatment of WHO Grade 2 Meningiomas With Stereotactic Radiosurgery: Identification of an Optimal Group for SRS Using RPA. Int J Radiat Oncol Biol Phys. 2021;110(3):804\u201314. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.048.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1766_CR44","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.wneu.2020.07.211","volume":"144","author":"CA Helis","year":"2020","unstructured":"Helis CA, Hughes RT, Cramer CK, Tatter SB, Laxton AW, Bourland JD, et al. Stereotactic Radiosurgery for Atypical and Anaplastic Meningiomas. World Neurosurg. 2020;144:e53\u201361. https:\/\/doi.org\/10.1016\/j.wneu.2020.07.211.","journal-title":"World Neurosurg"},{"issue":"6","key":"1766_CR45","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.3171\/2013.9.FOCUS13364","volume":"35","author":"D Ding","year":"2013","unstructured":"Ding D, Starke RM, Hantzmon J, Yen CP, Williams BJ, Sheehan JP. The role of radiosurgery in the management of WHO Grade II and III intracranial meningiomas. Neurosurg Focus. 2013;35(6):E16. https:\/\/doi.org\/10.3171\/2013.9.FOCUS13364.","journal-title":"Neurosurg Focus"},{"issue":"5","key":"1766_CR46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ijrobp.2019.04.011","volume":"104","author":"R CL","year":"2019","unstructured":"CL R. High-risk meningioma: Initial outcomes from NRG Oncology\/RTOG 0539. Int J Radiat Oncol Biol Phys. 2019;104(5):1046\u201354. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.04.011.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1766_CR47","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ijrobp.2011.08.010","volume":"83","author":"S Adeberg","year":"2012","unstructured":"Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, et al. Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas\u2013clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(3):859\u201364. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.08.010.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1766_CR48","doi-asserted-by":"publisher","first-page":"E99","DOI":"10.1093\/neuros\/nyab143","volume":"89","author":"MS Susko","year":"2021","unstructured":"Susko MS, Chen WC, Vasudevan HN, Magill ST, Lucas CG, Oberheim Bush NA, et al. Letter: Patterns of Intermediate- and High-Risk Meningioma Recurrence After Treatment With Postoperative External Beam Radiotherapy. Neurosurgery. 2021;89(1):E99\u2013101. https:\/\/doi.org\/10.1093\/neuros\/nyab143.","journal-title":"Neurosurgery"},{"issue":"2","key":"1766_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11060-019-03232-w","volume":"144","author":"JJB Lee","year":"2019","unstructured":"Lee JJB, Lee J, Yoon HI, Kim SH, Cho J, Lee KS, et al. Analysis of patterns of failure and appraisal of postoperative radiation field for grade II-III meningioma. J Neurooncol. 2019;144(2):333\u201341. https:\/\/doi.org\/10.1007\/s11060-019-03232-w.","journal-title":"J Neurooncol"},{"issue":"2","key":"1766_CR50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3171\/jns.1994.80.2.0195","volume":"80","author":"BJ Goldsmith","year":"1994","unstructured":"Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994;80(2):195\u2013201. https:\/\/doi.org\/10.3171\/jns.1994.80.2.0195.","journal-title":"J Neurosurg"},{"issue":"3","key":"1766_CR51","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ijrobp.2023.09.026","volume":"118","author":"KL Zeng","year":"2024","unstructured":"Zeng KL, Soliman H, Myrehaug S, Tseng CL, Detsky JM, Chen HM, et al. Dose-Escalated Radiation Therapy Is Associated With Improved Outcomes for High-Grade Meningioma. Int J Radiat Oncol Biol Phys. 2024;118(3):662\u201371. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.09.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1766_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11060-022-04206-1","volume":"161","author":"D Kim","year":"2023","unstructured":"Kim D, Chang WI, Byun HK, Kim IA, Cho J, Lee JH, et al. Dose-response relationship in patients with newly diagnosed atypical meningioma treated with adjuvant radiotherapy. J Neurooncol. 2023;161(2):329\u201337. https:\/\/doi.org\/10.1007\/s11060-022-04206-1.","journal-title":"J Neurooncol"},{"key":"1766_CR53","doi-asserted-by":"publisher","unstructured":"Jahanbakhshi A, Najafi M, Gomar M, Ciammella P, Ruggieri MP, Iotti C, et al. Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis. J Pers Med. 2024;14(8). https:\/\/doi.org\/10.3390\/jpm14080802.","DOI":"10.3390\/jpm14080802"},{"issue":"3","key":"1766_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ijrobp.2024.10.034","volume":"121","author":"F Ehret","year":"2025","unstructured":"Ehret F, El Baya L, Erridge SC, Bussiere M, Verhoeff JJC, Niyazi M, et al. Radiation Therapy for Meningiomas - Where Do We Stand and What\u2019s on the Horizon? Int J Radiat Oncol Biol Phys. 2025;121(3):599\u2013612. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.10.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1766_CR55","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/nop\/npad077","volume":"11","author":"S Gaito","year":"2024","unstructured":"Gaito S, Goyal L, Rieu R, France A, Burnet NG, Barker C, et al. Radiotherapy intensification for atypical and malignant meningiomas: A systematic review. Neurooncol Pract. 2024;11(2):115\u201324. https:\/\/doi.org\/10.1093\/nop\/npad077.","journal-title":"Neurooncol Pract"},{"issue":"6","key":"1766_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.7785\/tcrt.2012.500267","volume":"11","author":"AW Chan","year":"2012","unstructured":"Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS. Dose escalation with proton radiation therapy for high-grade meningiomas. Technol Cancer Res Treat. 2012;11(6):607\u201314. https:\/\/doi.org\/10.7785\/tcrt.2012.500267.","journal-title":"Technol Cancer Res Treat"},{"issue":"4","key":"1766_CR57","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.ijrobp.2017.07.008","volume":"99","author":"NN Sanford","year":"2017","unstructured":"Sanford NN, Yeap BY, Larvie M, Daartz J, Munzenrider JE, Liebsch NJ, et al. Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas. Int J Radiat Oncol Biol Phys. 2017;99(4):787\u201396. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.07.008.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1766_CR58","doi-asserted-by":"publisher","first-page":"123429","DOI":"10.1016\/j.wneu.2024.11.012","volume":"194","author":"RL Calafiore","year":"2025","unstructured":"Calafiore RL, Helis CA, Marcet P, Smith E, Ramsey B, Pacholke H, et al. Fractionated Radiotherapy With Stereotactic Radiosurgery Boost Controls Gross Disease in Grade 2 Meningioma. World Neurosurg. 2025;194:123429. https:\/\/doi.org\/10.1016\/j.wneu.2024.11.012.","journal-title":"World Neurosurg"},{"key":"1766_CR59","doi-asserted-by":"publisher","unstructured":"Krcek R, Leiser D, Garcia-Marqueta M, Bolsi A, Weber DC. Long Term Outcome and Quality of Life of Intracranial Meningioma Patients Treated with Pencil Beam Scanning Proton Therapy. Cancers (Basel). 2023;15(12). https:\/\/doi.org\/10.3390\/cancers15123099.","DOI":"10.3390\/cancers15123099"},{"key":"1766_CR60","doi-asserted-by":"publisher","unstructured":"EB AW. S, JP S. Particle therapy for high-grade meningiomas: a systematic review. Neurosurgical Focus. 2019;46(6):E10. https:\/\/doi.org\/10.3171\/2019.3.Focus1975.","DOI":"10.3171\/2019.3.Focus"},{"issue":"1","key":"1766_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13014-017-0948-9","volume":"13","author":"S A","year":"2018","unstructured":"A S, A A, A S. Carbon ion boost following photon radiotherapy for atypical meningioma (MARCIE): Phase II trial. Radiat Oncol. 2018;13(1):4. . https:\/\/doi.org\/10.1186\/s13014-017-0948-9","journal-title":"Radiat Oncol"},{"key":"1766_CR62","unstructured":"2016. https:\/\/clinicaltrials.gov\/study\/NCT02693990"},{"key":"1766_CR63","unstructured":"2016. https:\/\/clinicaltrials.gov\/study\/NCT02978677"},{"issue":"1","key":"1766_CR64","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1186\/s12885-024-13353-9","volume":"24","author":"P Lesueur","year":"2024","unstructured":"Lesueur P, Clarisse B, Lequesne J, Licaj I, Feuvret L, Stefan D, et al. Proton therapy versus conventional radiotherapy for the treatment of cavernous sinus benign meningioma, a randomized controlled phase III study protocol (COG-PROTON-01). BMC Cancer. 2024;24(1):1594. https:\/\/doi.org\/10.1186\/s12885-024-13353-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"1766_CR65","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3109\/09553001003667982","volume":"86","author":"FJ Vernimmen","year":"2010","unstructured":"Vernimmen FJ, Slabbert JP. Assessment of the alpha\/beta ratios for arteriovenous malformations, meningiomas, acoustic neuromas, and the optic chiasma. Int J Radiat Biol. 2010;86(6):486\u201398. https:\/\/doi.org\/10.3109\/09553001003667982.","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"1766_CR66","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13014-018-1026-0","volume":"13","author":"AA RA E-S","year":"2018","unstructured":"RA E-S AA. Particle therapy reirradiation for recurrent intracranial meningioma: outcomes and toxicity. Radiat Oncol. 2018;13(1):86. https:\/\/doi.org\/10.1186\/s13014-018-1026-0.","journal-title":"Radiat Oncol"},{"issue":"4","key":"1766_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.14338\/IJPT-18-00045.1","volume":"5","author":"BS Imber","year":"2019","unstructured":"Imber BS, Neal B, Casey DL, Darwish H, Lin AL, Cahlon O, et al. Clinical Outcomes of Recurrent Intracranial Meningiomas Treated with Proton Beam Reirradiation. Int J Part Ther. 2019;5(4):11\u201322. https:\/\/doi.org\/10.14338\/IJPT-18-00045.1.","journal-title":"Int J Part Ther"},{"issue":"9","key":"1766_CR68","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/0284186X.2023.2241994","volume":"62","author":"D Scartoni","year":"2023","unstructured":"Scartoni D, Giacomelli I, Pertile R, Vennarini S, Feraco P, Picori L, et al. Proton therapy re-irradiation provides promising clinical results in recurrent brain meningioma. Acta Oncol. 2023;62(9):1096\u2013101. https:\/\/doi.org\/10.1080\/0284186X.2023.2241994.","journal-title":"Acta Oncol"},{"key":"1766_CR69","doi-asserted-by":"publisher","first-page":"110271","DOI":"10.1016\/j.radonc.2024.110271","volume":"195","author":"I Desideri","year":"2024","unstructured":"Desideri I, Morelli I, Banini M, Greto D, Visani L, Nozzoli F, et al. Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors. Radiother Oncol. 2024;195:110271. https:\/\/doi.org\/10.1016\/j.radonc.2024.110271.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1766_CR70","doi-asserted-by":"publisher","first-page":"vdae073","DOI":"10.1093\/noajnl\/vdae073","volume":"6","author":"CM Harari","year":"2024","unstructured":"Harari CM, Burr AR, Morris BA, Tome WA, Bayliss A, Bhatia A, et al. Pulsed reduced-dose rate re-irradiation for patients with recurrent grade 2 gliomas. Neurooncol Adv. 2024;6(1):vdae073. https:\/\/doi.org\/10.1093\/noajnl\/vdae073.","journal-title":"Neurooncol Adv"},{"issue":"3","key":"1766_CR71","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ijrobp.2009.11.058","volume":"79","author":"JB Adkison","year":"2011","unstructured":"Adkison JB, Tome W, Seo S, Richards GM, Robins HI, Rassmussen K, et al. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):835\u201341. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.11.058.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1766_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-018-03011-z","volume":"141","author":"JS Witt","year":"2019","unstructured":"Witt JS, Musunuru HB, Bayliss RA, Howard SP. Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy. J Neurooncol. 2019;141(1):103\u20139. https:\/\/doi.org\/10.1007\/s11060-018-03011-z.","journal-title":"J Neurooncol"},{"issue":"5","key":"1766_CR73","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/neuonc\/nor044","volume":"13","author":"DR Johnson","year":"2011","unstructured":"Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530\u20135. https:\/\/doi.org\/10.1093\/neuonc\/nor044.","journal-title":"Neuro Oncol"},{"issue":"8","key":"1766_CR74","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cncr.23803","volume":"113","author":"MC Chamberlain","year":"2008","unstructured":"Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146\u201351. https:\/\/doi.org\/10.1002\/cncr.23803.","journal-title":"Cancer"},{"issue":"6","key":"1766_CR75","doi-asserted-by":"publisher","first-page":"E18","DOI":"10.3171\/2013.10.FOCUS13341","volume":"35","author":"AA Moazzam","year":"2013","unstructured":"Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus. 2013;35(6):E18. https:\/\/doi.org\/10.3171\/2013.10.FOCUS13341.","journal-title":"Neurosurg Focus"},{"key":"1766_CR76","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/sni.sni_264_17","volume":"9","author":"AJ Franke","year":"2018","unstructured":"Franke AJ, Skelton WI, Woody LE, Bregy A, Shah AH, Vakharia K, et al. Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review. Surg Neurol Int. 2018;9:133. https:\/\/doi.org\/10.4103\/sni.sni_264_17.","journal-title":"Surg Neurol Int"},{"issue":"1","key":"1766_CR77","doi-asserted-by":"publisher","first-page":"vdac123","DOI":"10.1093\/noajnl\/vdac123","volume":"4","author":"P Kumthekar","year":"2022","unstructured":"Kumthekar P, Grimm SA, Aleman RT, Chamberlain MC, Schiff D, Wen PY, et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022;4(1):vdac123. https:\/\/doi.org\/10.1093\/noajnl\/vdac123.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"1766_CR78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/neuonc\/nou148","volume":"17","author":"TJ Kaley","year":"2015","unstructured":"Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116\u201321. https:\/\/doi.org\/10.1093\/neuonc\/nou148.","journal-title":"Neuro Oncol"},{"issue":"3","key":"1766_CR79","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","volume":"26","author":"T Graillon","year":"2020","unstructured":"Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, et al. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clin Cancer Res. 2020;26(3):552\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2109.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1766_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/neuonc\/noab118","volume":"24","author":"WL Bi","year":"2022","unstructured":"Bi WL, Nayak L, Meredith DM, Driver J, Du Z, Hoffman S, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022;24(1):101\u201313. https:\/\/doi.org\/10.1093\/neuonc\/noab118.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1766_CR81","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","volume":"13","author":"PK Brastianos","year":"2022","unstructured":"Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022;13(1):1325. https:\/\/doi.org\/10.1038\/s41467-022-29052-7.","journal-title":"Nat Commun"},{"issue":"4","key":"1766_CR82","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C Mirian","year":"2021","unstructured":"Mirian C, Duun-Henriksen AK, Maier A, Pedersen MM, Jensen LR, Bashir A, et al. Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. J Nucl Med. 2021;62(4):507\u201313. https:\/\/doi.org\/10.2967\/jnumed.120.249607.","journal-title":"J Nucl Med"},{"issue":"2","key":"1766_CR83","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.ijrobp.2024.07.003","volume":"120","author":"KW Merrell","year":"2024","unstructured":"Merrell KW, Johnson DR, Steinert KO, Ruff M, Breen W, Gunn HJ, et al. A Prospective, Phase II Study of <\u2009sup>177\u2009Lu-Dotatate in Patients with Surgery- and Radiation-Refractory Meningioma: Results of the WHO Grade II\/III Cohort. Int J Radiat Oncol Biol Phys. 2024;120(2):S11\u20132. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1766_CR84","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00259-025-07336-6","volume":"53","author":"N Hasenauer","year":"2025","unstructured":"Hasenauer N, Muller M, Hanscheid H, Serfling SE, Michalski K, Heinrich M, et al. SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. Eur J Nucl Med Mol Imaging. 2025;53(1):116\u201327. https:\/\/doi.org\/10.1007\/s00259-025-07336-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1766_CR85","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","volume":"30","author":"SC Kurz","year":"2024","unstructured":"Kurz SC, Zan E, Cordova C, Troxel AB, Barbaro M, Silverman JS, et al. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024;30(4):680\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2533.","journal-title":"Clin Cancer Res"},{"issue":"Supplement5","key":"1766_CR86","doi-asserted-by":"publisher","first-page":"v422","DOI":"10.1093\/neuonc\/noaf201.1671","volume":"27","author":"SC Kurz","year":"2025","unstructured":"Kurz SC, Rabbee N, Wen PY, Kalapurakal JA, Peereboom DM, Bi LW, et al. TIP-11. MOMENTUM-1: a multicenter, randomized, open-label, phase 2 study of [177Lu]Lu-DOTA-TATE in adults with progressive grade 1\u20133 meningioma (RTOG 3523). Neurooncology. 2025;27(Supplement5):v422\u2013v. https:\/\/doi.org\/10.1093\/neuonc\/noaf201.1671.","journal-title":"Neurooncology"},{"key":"1766_CR87","unstructured":"2024. https:\/\/clinicaltrials.gov\/study\/NCT06326190"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01766-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:27:29Z","timestamp":1781648849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01766-7","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines). The authors declare no competing interests, conflicts of interest, or disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights:"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"42"}}